Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Axxcess Wealth Management LLC

Axxcess Wealth Management LLC decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRLGet Rating) by 19.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,995 shares of the medical research company’s stock after selling 467 shares during the quarter. Axxcess Wealth Management LLC’s holdings in Charles River Laboratories International were worth $426,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of CRL. Trustcore Financial Services LLC acquired a new position in shares of Charles River Laboratories International during the first quarter valued at approximately $28,000. Trust Co. of Vermont acquired a new position in shares of Charles River Laboratories International during the second quarter valued at approximately $29,000. Covestor Ltd raised its holdings in shares of Charles River Laboratories International by 100.0% during the first quarter. Covestor Ltd now owns 174 shares of the medical research company’s stock valued at $49,000 after acquiring an additional 87 shares during the last quarter. First Horizon Advisors Inc. raised its holdings in shares of Charles River Laboratories International by 110.8% during the second quarter. First Horizon Advisors Inc. now owns 253 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 133 shares during the last quarter. Finally, Sugarloaf Wealth Management LLC raised its holdings in shares of Charles River Laboratories International by 33.8% during the second quarter. Sugarloaf Wealth Management LLC now owns 285 shares of the medical research company’s stock valued at $61,000 after acquiring an additional 72 shares during the last quarter. Institutional investors and hedge funds own 95.20% of the company’s stock.

Insiders Place Their Bets

In other Charles River Laboratories International news, CAO Michael Gunnar Knell sold 855 shares of the company’s stock in a transaction on Wednesday, November 16th. The stock was sold at an average price of $248.59, for a total transaction of $212,544.45. Following the transaction, the chief accounting officer now directly owns 6,438 shares in the company, valued at $1,600,422.42. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, EVP Shannon M. Parisotto sold 2,279 shares of the stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $249.90, for a total value of $569,522.10. Following the sale, the executive vice president now directly owns 2,499 shares in the company, valued at $624,500.10. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CAO Michael Gunnar Knell sold 855 shares of the stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $248.59, for a total value of $212,544.45. Following the completion of the sale, the chief accounting officer now owns 6,438 shares in the company, valued at $1,600,422.42. The disclosure for this sale can be found here. Insiders have sold 3,668 shares of company stock worth $897,603 over the last ninety days. Corporate insiders own 1.10% of the company’s stock.

Charles River Laboratories International Trading Down 0.4 %

Shares of Charles River Laboratories International stock opened at $241.08 on Thursday. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.14 and a current ratio of 1.40. The stock has a 50 day moving average of $211.63 and a 200 day moving average of $219.06. Charles River Laboratories International, Inc. has a fifty-two week low of $181.36 and a fifty-two week high of $385.11. The firm has a market capitalization of $12.27 billion, a price-to-earnings ratio of 28.40, a PEG ratio of 1.59 and a beta of 1.28.

Analyst Ratings Changes

A number of equities analysts have commented on CRL shares. Evercore ISI reduced their target price on Charles River Laboratories International to $260.00 in a report on Tuesday, August 9th. Jefferies Financial Group upgraded Charles River Laboratories International from a “hold” rating to a “buy” rating and set a $240.00 price target for the company in a research report on Thursday, September 29th. JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $280.00 to $275.00 and set an “overweight” rating for the company in a research report on Thursday, November 3rd. Citigroup dropped their price target on Charles River Laboratories International to $280.00 in a research report on Tuesday, August 9th. Finally, Wells Fargo & Company dropped their price target on Charles River Laboratories International from $325.00 to $300.00 and set an “overweight” rating for the company in a research report on Tuesday, August 16th. Three investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and an average target price of $298.42.

About Charles River Laboratories International

(Get Rating)

Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Further Reading

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRLGet Rating).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.